Definitive Contract HHSO100200500007C
Award Date 9/27/05
Potential Completion Date 9/30/23
Potential Value $161M
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Combination (two or more)
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Clinger Cohen Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...
- <p>This is a Cost Plus Fixed Fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Altimmune, Inc. for the development of a single-dose intranasal vaccine for post-exposure prophylaxis of inhalation anthrax. The award has a ceiling value of $135,880,962.00 and a period of performance through December 31, 2021. The contract was awarded on July 27, 2016 and does not have a set-aside designation.</p>
- This is a $1,628,690,592.00 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Bavarian Nordic A/S, a for-profit biotechnology company based in Denmark. The contract has a firm fixed price pricing type and an ultimate completion date of September 26, 2027. It is not a set-aside contract. Bavarian Nordic A/S is providing the government with various goods and services, including endpoint titer analysis services involving...
- This is a $1,054,186.47 delivery order contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to The Texas A&M University System for the Centers for Innovation in Advanced Development and Manufacturing program. The contract involves technology transfer and cGMP (current Good Manufacturing Practice) manufacture of an adenovirus type 5 (Ad5) vectored anthrax vaccine. No set-aside was used. The prime contractor, Texas A&M...
- This is a federal contract award from the U.S. Department of Health and Human Services (HHS) to Elusys Therapeutics Inc., a for-profit organization and manufacturer of goods. The contract, valued at $44,971,900.00, is for "OTHER FUNCTIONS" and is a Firm Fixed Price Delivery Order with no set-aside designation. Elusys Therapeutics Inc. specializes in biomedical research and development, with a focus on advanced technology. The contract is related to the "ANTHIM" product, which...
- This is a $65,867,803.99 definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to VIR Biotechnology, Inc., a self-certified small disadvantaged business. The contract is for the development of pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens with pandemic potential. This contract was awarded under a Broad...
- This is a definitive contract awarded by the Department of the Army's Joint PEO Chemical and Biological Defense, a defense agency, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $366,290,602.35 cost-plus-fixed-fee contract is for the Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) Capability, with a period of performance through October 31, 2023. As a prime contractor, Resilience has provided a range of goods and services related...
- This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Macrogenics, Inc., a for-profit manufacturer, for research and development services related to advanced development. The contract has a ceiling value of $56,058,625.93 and was awarded on September 29, 2006, with an ultimate completion date of September 28, 2011. The contract is not set-aside for any...
- This federal contract award is for the development of CD388 as a long-lasting prophylactic anti-viral option to protect against the health impacts caused by influenza. The $339,189,481.00 definitive, cost-plus-fixed-fee contract was awarded to Cidara Therapeutics Inc., a for-profit organization, by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, on September 30, 2025. The contract has an ultimate completion date of July 3, 2030 and was not set aside for...
- The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $481.7 million cost-plus-fixed-fee definitive contract to Shionogi Inc. on April 6, 2026, for late-stage development, FDA marketing authorization, procurement, and stockpiling of antibiotics to treat drug-resistant secondary bacterial infections and infections caused by biothreat pathogens. The contract, which extends through March 10, 2036, supports ASPR's...